Dry Eye Clinical Trial
Official title:
Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears
Verified date | April 2020 |
Source | Northeastern State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
Osmolarity is defined as the concentration of particles dissolved in a solution. Normal tears
contain various dissolved particles including proteins, salts and other electrolytes. The
investigators plan to investigate how osmolarity of the tear film changes over time after
instillation of artificial tears containing hyaluronate. This is one kind of artificial tear
that is used to treat dry eye.
Dry eye and tear osmolarity:
Dry eye is a significant health problem, but diagnosis and treatment are often ambiguous and
ineffective. There has been a resurgence of interest and research in dry eye in the past 5
years, and tear osmolarity has emerged as perhaps, one of the most effective ways to evaluate
tear quality and dry eye status. Dry eye is usually treated with artificial tears, and many
formulations are available. The investigators will test an isotonic solution that contains
hyaluronate. Hyaluronate binds water and should help to maintain water on the eye.
Objective:
We plan to study the time course of possible changes in tear film osmolarity following
instillation of an isotonic artificial tear containing hyaluronate. The investigators will
use the TearLab, a new clinical instrument that has been developed to quickly and easily
measure tear film osmolarity. Understanding how artificial tears affect tear film osmolarity
over time can help doctors determine efficacy and dosing schedules. The investigators will
test the isotonic hyaluronate (Blink Contacts) artificial tears relative to normal saline
solution.
Hypothesis:
The investigators should be able to measure a decrease in tear osmolarity over time following
instillation due to the water-binding effect of hyaluronate artificial tears relative to a
control (normal saline solution).
Status | Completed |
Enrollment | 8 |
Est. completion date | August 2012 |
Est. primary completion date | August 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: - At least 18 years of age Normal vision in both eyes (20/30 best corrected) Preference for patient with dry eye symptoms Exclusion Criteria: - No ocular disease other than dry eye Currently taking no ocular or systemic medications that might affect results |
Country | Name | City | State |
---|---|---|---|
United States | Northeastern State University | Tahlequah | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Thomas O Salmon, OD, PhD |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Osmolarity Change From Baseline (mOsms/L) as a Function of Time (Minutes) | Raw data: Baseline (pre-instillation) tear osmolarity was measured for right and left eyes for each subject. Then measurements were repeated at 7 times (5, 20, 35, 50, 65 890 and 95 minutes) after instillation. Data processing: 1) Baseline osmolarity was subtracted from each post-baseline measurement to give a change-from-baseline values. 2) Right and left eye change values averaged to give a mean osmolarity change for each subject at each of the seven times. 3) Mean osmolarity changes values were averaged across 8 subjects for each of the 7 times and entered in the table below. Row 1 is for Drop A (hyaluronate); Row 2 for Drop B (saline). Column are for the 7 times. | Baseline, followed by 7 measurements made after instillation (5, 20, 35, 50, 65, 80, 95 minutes post-instillation). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |